November 29, 202349 leaders from Heilongjiang Province and various cities in Heilongjiang visited Beike Biotech for inspection and research. Dr. Hu Junyuan, Chairman of Shenzhen Beike Biotechnology Co., Ltd., warmly received the Heilongjiang government research team.
The research team visited Shenzhen comprehensive cell bank, fully automatic cell intelligent manufacturing system and Beike Biolife Science Experience Centeretc. The delegation observed the production scene of the first (set) new fully automatic cell intelligent manufacturing system introduced and deployed by Beike Biotechnology. They saw that cells that can cure diseases and save lives were in the unattended workshop. Through the “instructions” of the automated intelligent system, SOPs were automatically executed to complete the production of cell products. The simulated production control built through digital means can intuitively reflect the production process, cell status, etc. of the unattended workshop. Later at the Beike Bio Life Science Experience Center, the research team also gained a deeper understanding of Beike Bio’s intelligent cell preparation technology and scientific research results.
At the subsequent symposium, Dr. Hu Junyuan, chairman of Beike Biotech, introduced Beike Biotech’s “artificial intelligence +” layout in the biomedical field to the leaders of the research group.It emphasized that under the background of the rapid development of personalized precision medicine, an intelligent manufacturing system built with intelligence, automation, and digitalization as the core that can produce efficiently and respond quickly will become the focus of industry competition in the future of the cell industry. The bioeconomy is a new driving force for future industrial growth and is also a strategic leading industry in Heilongjiang Province’s “14th Five-Year Plan”. As one of the subdivisions of the bioeconomy, the cell industry is an important area for industrial improvement in Heilongjiang Province. As the “leader” in the domestic cell field, Beike Biotech hopes to inject new momentum into the high-quality development of Heilongjiang’s biomedicine and health industries in this black land, accelerate its progress, benefit Heilongjiang with cell technology, and create favorable conditions for a better life for the people.
"Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; letter-spacing: 0.544px; text-align: center; white-space: pre-wrap; background-color: rgb(1, 152, 88); box-sizing: border-box !important; overflow-wrap: break-word !important;”>Extended reading
Harbin Beike Biotech was approved to undertake the national industrialization project
Harbin Beike Health Technology Co., Ltd., a subsidiary of Beike Biotech, was approved to assume national responsibility !important;”>“Biotechnology and Information Fusion Application Engineering”Topic 2 in direction one”Development and promotion of biopharmaceutical digital intelligent production line” construction tasks. This project revolves around the key aspects of cell preparation manufacturing,Using cloud computing, industrial Internet, big data, artificial intelligence and other information technologies to digitalize and intelligently upgrade the entire production system and establish a standardized and modular intelligent intelligent manufacturing platform, it can shorten the construction cycle of traditional cell preparation factories by more than 25%, strengthen key equipment data collection and visual management, improve quality control and production efficiency by more than 30%, and the localization rate of production line equipment, software and hardware exceeds 93.7%.
Harbin Beike will use the fully enclosed digital intelligent production line of cell preparations independently developed by its partner Saidong Intelligent Manufacturing to realize the mass production of rFib repair fibroblasts, form a demonstration of “integrated application of biotechnology and information technology” in the production of cell preparations, and provide third-party cell preparation production services to relevant social R&D enterprises and scientific research institutions.Promote a huge improvement in the level of production line technology and equipment in the field of biopharmaceutical cell gene therapy (CGT) products, reaching the international leading level.